You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The effect of TLR4 inhibition on lung transplant ischemia-reperfusion injury

    SBC: X-IN8 BIOLOGICALS CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) occurs in organs when circulation is interrupted, causing ischemia, and then ischemic tissue is reperfused. This leads to a series of biologic consequences, resulting in edema and inflammation. IRI is a significant problem in organ transplantation, because IRI is the major cause of primary graft failure and organ dysfunction af ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. PROTOTYPE CATHETER FOR IN VIVO HIGH-RESOLUTION CARDIAC FLUORESCENCE MAPPING

    SBC: CARDIOFOCUS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this project is to develop a system to optically record fluorescence signals from heart tissues in vivo. Fluorescent dyes have been used to record biological processes from the heart for more than a decade. Specifically, staining the heart with voltage-sensitive dyes -which emit fluorescence that varies with the membrane potential-and using hig ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a BBB Model to Study Transendothelial Cell Migration

    SBC: Flocel Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): Increasing evidence indicates that systemic inflammation and the blood-brain barrier (BBB), which becomes the target of overreacting or misguided immune cells that determine BBB failure and immune extravasations into the brain parenchyma, are involved in the pathogenesis of neurological diseases such as meningitis, inflammation, Alzheimer's disease, and multipl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Neuroprotective therapy of stroke with HUCNC and simvastatin

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Identification and Characterization of Causative Genetic Biomarkers for Parkinson

    SBC: POPULATION DIAGNOSTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): The goal of this project is to rapidly discover biomarkers for Parkinson's Disease (PD) by defining the spectrum of causal genetic loci for PD, not only for the purpose of accurate diagnosis and risk stratification but also in order to shed light on the underlying biology and pathways involved in PD pathogenesis for the purpose of future rational therapeutic de ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Hybernia Safety Catheter for Neuroprotection via Selective Hypothermia

    SBC: Hybernia Medical, LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): Hypothermia is a powerful neuroprotective treatment for ischemic injury and is indicated for use in cardiopulmonary bypass, cardiac arrest, and neonatal hypoxia. However, current methods induce systemic hypothermia which requires significant time and has associated complications. Hybernia Medical, LLC is developing a device based on intellectual property assign ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Diagnostic Assay for Thrombocytosis

    SBC: STONY BROOK BIOTECHNOLOGY            Topic: NCRR

    DESCRIPTION (provided by applicant): Our goal is to develop an In Vitro Diagnostic Multivariate Assay (IVDMIA) to distinguish Essential Thrombocythemia (ET) from non-clonal reactive thrombocytosis (RT) etiologies. ET represents a distinct subtype of myeloproliferative disorders, thrombocytosis, characterized by increased proliferation of megakaryocytes and resultant elevated levels of circulating ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Quit IT: Development of a Web-based 3D Coping Skills Game to Increase Self-Effic

    SBC: Muzzy Lane Software            Topic: NIDA

    DESCRIPTION (provided by applicant): Tobacco use remains the single most preventable cause of premature deaths and cancer.1 Building on more than a decade of clinical and research experience in treating tobacco-dependence, we propose to address this problem with a new academic-small computer game business partnership that will develop a novel e-health tobacco cessation and relapse prevention produ ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Intranasal Naloxone: An Opioid Overdose Antidote

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): There is a significant unmet medical need to provide additional pharmacologic treatments for treatment and prevention of opioid overdose. This Fast Track STTR project proposes to apply drug delivery technologies to develop a novel use for a nasally delivered pharmaceutical - naloxone (NLX) hydrochloride - for the emergency treatment of opioid overdose by emerge ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government